Indivior PLC

Regulatory Filings • May 24, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0617P

Indivior PLC

24 May 2018

Indivior's Mark Crossley to Participate in Jefferies 2018 Global Healthcare Conference on June 5th

Slough, UK, May 24, 2018 - Indivior PLC (LON: INDV) today announced that Mark Crossley, CFO, will participate in Jefferies 2018 Global Healthcare Conference on Tuesday, June 5th, 2018, at 8:30 a.m. local time, in New York City. Crossley will discuss Indivior's business and outlook. His remarks will be webcast live and the broadcast will be available on the "Investors" section of Indivior's website (www.indivior.com). If you plan on listening to the live webcast please allow sufficient time to register and download any audio software required to access the discussion.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 1000 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-423-8916 or jason.thompson@indivior.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCFKNDQBBKDFPB